O-304 (ATX) 100mg – 30 capsules Product Information
O-304 100 mg — 30 oral research capsules. O-304 is one of the most pharmacologically distinctive metabolic compounds in active development — the only well-characterized pan-AMPK activator that operates through direct allosteric binding at the AMPK γ-subunit, with concurrent autotaxin (ATX) / lysophosphatidic acid (LPA) signaling modulation. AMPK is the master energy-sensing kinase of the cell, the same target activated by metformin, and the principal mediator of the metabolic effects of exercise. O-304 produces direct AMPK activation at vastly lower micromolar concentrations than metformin, with documented effects on glucose homeostasis, capillary density, and microvascular function in randomized clinical trials in type-2 diabetes — placing it in a unique position at the intersection of metabolic and microvascular pharmacology. RESEARCH USE ONLY · Not for human or veterinary use. For laboratory and collector purposes only. Purity ≥ 98 % (HPLC) — third-party tested, CoA on file Form Research capsules Content 100 mg O-304 per capsule Total 30 capsules per bottle (3 g total) Packaging Sealed bottle with tamper-evident closure Storage Room temperature, dry, protected from light Target AMP-activated protein kinase (AMPK) — direct pan-isoform activator Secondary mechanism Autotaxin / lysophosphatidic acid (LPA) signaling modulation Synonyms O-304; pan-AMPK activator; ATX modulator Research Overview O-304 is a direct, pan-isoform allosteric activator of AMP-activated protein kinase (AMPK) — the master cellular energy sensor that orchestrates the metabolic response to exercise, fasting and substrate scarcity [1]. AMPK activation upregulates fatty-acid β-oxidation, mitochondrial biogenesis, GLUT4-mediated glucose uptake and autophagy, while suppressing gluconeogenesis, lipogenesis and protein synthesis — the integrated metabolic phenotype of exercise [1,2]. Unlike metformin, which activates AMPK indirectly via Complex-I inhibition, O-304 binds the AMPK γ-subunit directly and produces sustained activation across all three AMPK heterotrimer combinations [1]. In a Phase II clinical trial in type-2 diabetes, oral O-304 produced significant reductions in fasting plasma glucose, HbA1c, and — uniquely — measurable improvements in microvascular function and capillary density assessed by skin-microcirculation imaging [2]. The microvascular effect is attributed to a parallel mechanism through autotaxin / LPA signaling, providing a molecular explanation for why type-2 diabetes microvascular complications are responsive to this molecule but not to other AMPK activators [3]. Primary Research Areas Direct AMPK pharmacology — the leading direct pan-AMPK activator with γ-subunit allosteric binding; the cleanest research probe of AMPK pharmacology distinct from metformin’s indirect activation [1,2]. Type-2 diabetes and metabolic syndrome — Phase II RCT evidence of fasting-glucose and HbA1c reduction in T2D cohorts [2]. Microvascular function — uniquely improves capillary density and microvascular flow — an effect attributable to the parallel ATX/LPA mechanism not present in other AMPK activators [2,3]. Exercise-mimetic pharmacology — produces the metabolic transcriptional signature of training adaptation in skeletal muscle and adipose tissue [1]. Autotaxin / LPA signaling — the secondary mechanism, of independent interest for studying microvascular biology and fibrosis pharmacology [3]. References Steneberg P, Lindahl E, Dahl U, et al. PAN-AMPK activator O304 improves glucose homeostasis and microvascular perfusion in mice and type 2 diabetes patients. JCI Insight. 2018;3(12):e99114. Eldrup E, Andersen JR, Bode-Boger SM, et al. The AMPK activator O304 improves microvascular function in patients with type 2 diabetes — a randomized clinical trial. Diabetes Obes Metab. 2022;24(4):704–711. Garcia D, Shaw RJ. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol Cell. 2017;66(6):789–800.
